Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 6/20 | 0.81 |
| ▸ | FAAH | O00519 | 4/20 | 0.81 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | ABHD16A | O95870 | 2/20 | 0.47 |
| ▸ | LIPC | P11150 | 2/20 | 0.46 |
| ▸ | LIPE | Q05469 | 2/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.43 |
| ▸ | LPL | P06858 | 1/20 | 0.42 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | TACR3 | P29371 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7042914 | 0.90 | MGLL (1.00) | MGLLFAAHNPC1RAB9AABHD16A | |
| SCHEMBL29499689 | 0.90 | MGLL (1.00) | MGLLFAAHNPC1RAB9AABHD16A | |
| SCHEMBL7045850 | 0.87 | MGLL (0.72) | MGLLFAAHNPC1RAB9AABHD16A | |
| SCHEMBL7046374 | 0.80 | MGLL (0.83) | MGLLFAAHNPC1RAB9ALIPC | |
| SCHEMBL7040893 | 0.80 | MGLL (0.83) | MGLLFAAHNPC1RAB9ALIPC | |
| SCHEMBL7043936 | 0.80 | MGLL (0.82) | MGLLFAAHNPC1RAB9AABHD16A | |
| SCHEMBL7039924 | 0.80 | MGLL (0.81) | MGLLFAAHNPC1RAB9ALIPC | |
| SCHEMBL7044232 | 0.78 | MGLL (0.68) | MGLLFAAHNPC1RAB9A | |
| SCHEMBL7046148 | 0.78 | MGLL (0.78) | MGLLFAAHABHD16ALIPCLIPE | |
| SCHEMBL7045650 | 0.77 | MGLL (0.61) | MGLLFAAHNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030236288-A1 | Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-12-25 | — | — | US | disclosed |
| US-6369088-B2 | ANTIDIABETIC AGENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-09 | — | — | US | disclosed |
| US-20010031772-A1 | Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031772-A1 | Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and their use as pharmaceuticals | CNR1, PTGER1, CNR2 | MGLL 1542/4885FAAH 46/4885NPC1 622/4885 |
| US-20030236288-A1 | Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase | PNLIP, CEL, LIPE | MGLL 10/4885FAAH 142/4885NPC1 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.